Skip to main content

Compare Stocks

Date Range: 

 Viridian TherapeuticsSirona BiochemInhibikase TherapeuticsProMIS NeurosciencesOKYO Pharma
SymbolNASDAQ:VRDNCVE:SBMNYSE:IKTTSE:PMNLON:OKYO
Price Information
Current Price$17.52C$0.30$4.90C$0.19GBX 6.20
52 Week RangeBuyN/ABuyN/AN/A
MarketRank™
Overall Score1.70.51.00.50.5
Analysis Score3.50.00.00.00.0
Community Score5.02.45.02.72.3
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score0.00.00.00.00.0
Analyst Ratings
Consensus RecommendationBuyN/ABuyN/AN/A
Consensus Price Target$34.00N/AN/AN/AN/A
% Upside from Price Target94.06% upsideN/AN/AN/AN/A
Trade Information
Market Cap$68.47 millionC$58.80 million$49.29 millionC$56.60 million£42.05 million
BetaN/AN/AN/AN/AN/A
Average Volume50,194120,92281,068385,463361,036
Sales & Book Value
Annual RevenueN/AC$123,870.00N/AC$1,787.00N/A
Price / SalesN/A551.37N/A31,673.61N/A
CashflowN/AC$0.00 per shareN/AC$0.00 per shareGBX 0.82 per share
Price / CashN/A75.00N/A43.757.59
Book ValueN/AC$0.00 per shareN/AC$0.00 per shareGBX 0.80 per share
Price / BookN/A-150.00N/A-46.25N/A
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSN/AC($0.01)N/AC($0.02)GBX (0.10)
Trailing P/E Ratio0.00N/A0.00N/AN/A
Forward P/E Ratio∞∞∞∞∞
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A2,620.27%N/AN/A0.41%
Current RatioN/A1.59%N/A0.52%17.94%
Quick RatioN/A1.57%N/A0.46%17.82%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees26N/A3N/A4
Shares Outstanding3.91 million227.66 million10.06 million305.95 million672.82 million
Next Earnings Date8/4/2021 (Estimated)N/A7/1/2021 (Estimated)N/AN/A
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO announces appointment of Dr Rajkumar Patil as Chief Scientific OfficerOKYO Pharma Limited ("OKYO" or the "Company") - OKYO announces appointment of Dr Rajkumar Patil as Chief Scientific Officer
feeds.benzinga.com - March 29 at 2:43 AM
OKYO Pharma focused on getting its dry eye treatment into the clinic and to proof of conceptOKYO Pharma focused on getting its dry eye treatment into the clinic and to proof of concept
proactiveinvestors.co.uk - March 10 at 3:01 AM
OKYO Pharma Limited ("OKYO" or the "Company") - Result of the Annual General MeetingOKYO Pharma Limited ("OKYO" or the "Company") - Result of the Annual General Meeting
finance.yahoo.com - March 9 at 11:51 AM
OKYO Pharma (LON:OKYO) Is In A Strong Position To Grow Its BusinessOKYO Pharma (LON:OKYO) Is In A Strong Position To Grow Its Business
finance.yahoo.com - March 9 at 11:51 AM
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO announces filing of a patent application covering the use of Chemerin and associated analogues to treat “cytokine storm” associated with COVID-19 and ARDSOKYO Pharma Limited ("OKYO" or the "Company") - OKYO announces filing of a patent application covering the use of Chemerin and associated analogues to treat “cytokine storm” associated with COVID-19 and ARDS
finance.yahoo.com - March 9 at 11:51 AM
OKYO Pharma Limited ("OKYO" or the "Company") - Issue of EquityOKYO Pharma Limited ("OKYO" or the "Company") - Issue of Equity
finance.yahoo.com - March 9 at 11:51 AM
OKYO Pharma Limited ("OKYO" or the "Company") - Appointment of Dr. Napoleone Ferrara to Serve on Its Scientific Advisory BoardOKYO Pharma Limited ("OKYO" or the "Company") - Appointment of Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board
feeds.benzinga.com - August 19 at 2:40 AM
DateCompanyBrokerageAction
1/25/2021Viridian TherapeuticsLADENBURG THALM/SH SHInitiated Coverage
1/20/2021Viridian TherapeuticsJefferies Financial GroupBoost Price Target
4/26/2021Inhibikase TherapeuticsThinkEquityInitiated Coverage
2/17/2019ProMIS NeurosciencesNoble FinancialReiterated Rating
11/29/2019OKYO PharmaShore CapitalReiterated Rating
(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.